ACAD
30.46
-0.59
-1.90%
AEMD
0.25
0.00
-1.19%
APRI
1.39
-0.04
-2.80%
ARNA
4.32
-0.2
-4.32%
ATEC
1.29
-0.02
-1.53%
CFN
59.33
-0.28
-0.46%
CNAT
5.82
-0.14
-2.35%
CRXM
0.21
0.00
-1.38%
CYTX
0.48
+0.01
+1.89%
DXCM
59.81
-1.19
-1.95%
GNMK
12.89
-0.42
-3.16%
HALO
14.29
-0.3
-2.06%
ILMN
195.68
-4.32
-2.16%
INNV
0.22
+0.01
+4.19%
INO
8.33
-0.17
-2.00%
ISCO
0.06
0.00
0.00%
ISIS
68.56
-1.3
-1.86%
LGND
56.43
-0.6
-1.05%
LPTN
2.76
-0.09
-3.16%
MBVX
1.04
-0.01
-0.95%
MEIP
3.98
+0.12
+3.11%
MNOV
3.79
+0.02
+0.53%
MRTX
20.67
-0.62
-2.91%
MSTX
0.45
+0.01
+3.37%
NBIX
33.71
-0.64
-1.86%
NUVA
46.31
-0.99
-2.09%
ONCS
0.36
-0.01
-2.74%
ONVO
6.41
-0.28
-4.19%
OREX
5.26
-0.1
-1.78%
OTIC
29.25
-2.32
-7.35%
QDEL
23.53
-0.94
-3.84%
RCPT
110.06
-2.65
-2.35%
RGLS
19.15
+0.57
+3.04%
RMD
62.52
-0.51
-0.81%
SCIE
0.01
0.00
-2.65%
SPHS
0.48
+0.01
+1.34%
SRNE
10.1
-0.68
-6.31%
TROV
6.48
+0.65
+11.17%
VICL
1.03
-0.01
-0.96%
VOLC
17.96
0.00
0.00%
ZGNX
1.36
-0.01
-0.74%
Home » Archive by Category

Drug Discovery

San Diego’s Antibody-Drug Conjugate Research Highlighted at #WorldADC Meeting in October

November 24, 2014 – 8:11 am | Edit Post

San Diego was host to the World Antibody Drug Conjugate (ADC) Meeting and Awards October 26-29th 2014. ADCs are an exciting new class of oncology therapeutics utilizing monoclonal antibodies conjugated to cytotoxic drugs, resulting in …

SDBN August 21st 2012 Event At The Sanford Consortium For Regenerative Medicine

August 3, 2012 – 12:41 pm | Edit Post

The Sanford Consortium for Regenerative Medicine is a stem cell research facility representing a collaboration between five of San Diego’s finest research institutions: Sanford-Burnham Medical Research Institute, The Salk Institute, The Scripps Research Institute and …

SDBN June 25th Event With Lilly: Open Innovation Drug Discovery

June 4, 2012 – 1:48 am | Edit Post

San Diego biotech has grown thanks to a collaborative spirit which is sometimes manifested in the acquisition and joining of companies towards a common goal. Lilly’s presence here is indicative of this type of growth, …

San Diego’s Biotechnology Companies: Who’s Taking Off?

March 8, 2012 – 9:13 am | Edit Post

Here at SDBN we’ve been updating our directory of 400+ San Diego biotech companies.  We were surprised to find close to 40 companies removed from the local scene – due to acquisition or shut down.  …

SDBN March 26th 2012 Event with Organovo

March 6, 2012 – 1:59 pm | Edit Post

Organovo is an exciting San Diego biotech company with technology to create human tissue through a technique called 3D bioprinting. The tissue can be used for drug discovery and development, and the company has been …

Focus on San Diego: Life Science Conferences Spring 2012

January 31, 2012 – 11:56 am | Edit Post

This spring San Diego downtown will be buzzing with scientific discussions as our city hosts a number of major scientific symposia.  We are excited to attend and soak in all the science that will be …

Virtual Biotech Part 1: What We Learned About Effectively Outsourcing a Drug Discovery Program

July 28, 2011 – 12:04 pm | Edit Post
virtual drug discovery SDBN Event

The first in our Virtual Biotech series, our July 19th event was a success.  Thanks to our participants – some of San Diego’s leading virtual drug discovery scientists and CROs – for sharing their valuable …

SDBN July 19th Event: Virtual Biotech Part 1: How to Effectively Outsource a Drug Discovery Program

July 1, 2011 – 3:47 pm | Edit Post

Changes in the drug discovery landscape have presented many tough challenges for our region, including downsizing for larger companies and a dearth of VC funding for startups. With these challenges come opportunities, however, because drug …

SDBN June 21st Event Featuring aTyr Pharma

May 27, 2011 – 9:58 am | Edit Post

The San Diego Biotechnology Network’s June 21st event will feature aTyr Pharma, with Board Member and CEO Jeffry Watkins (Bio) giving a talk titled “Innovation: Where is our Biology?” aTyr is developing therapeutics based on …

SDBN April 19th 2011 Event Featuring Celgene

March 22, 2011 – 6:15 pm | Edit Post

Through research, acquisitions, and mergers, Celgene has built a robust product portfolio and pipeline in hematology and oncology. This accomplishment is quite a feat in today’s environment, with pharma pipelines dwindling, and they are one …